Tumor Inhibiting Properties of Stereoisomeric [1,2-Bis (3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-Complexes, Part II: Biological Properties-Reference-Cited by-同舟云学术

Tumor Inhibiting Properties of Stereoisomeric [1,2-Bis (3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-Complexes, Part II: Biological Properties

Published:1989 Issue:2 Volume:322 Page:67-73
ISSN:0365-6233
Container-title:Archiv der Pharmazie
language:de
Short-container-title:Arch. Pharm. Pharm. Med. Chem.

Author:

Jennerwein Margaretha,Gust Ronald,Müller Richard,Schönenberger Helmut,Engel Jürgen,Berger Martin R.,Schmähl Dietrich,Seeber Siegfried,Osieka Reinhanidt,Atassi Ghanem,Bock Danièle Maréchal-De

Publisher

Wiley

Subject

Drug Discovery,Pharmaceutical Science

Reference17 articles.

1. Tumor Inhibiting Properties of Stereoisomeric [1,2-Bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-Complexes, Part I: Synthesis

2. Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma

3. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cellsin vitro

4. CIS-dichlorodiammineplatinum (II)

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Relation Between Stereochemistry and Biological Activity of Platinum(II) Complexes Chelated with Chiral Diamine Ligands: An Intricate Problem;Current Pharmaceutical Design;2007-09-01

2. Synthesis and Cytotoxicity of Enantiomerically Pure [1,2-Diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) Complexes;ChemMedChem;2006-06-12

3. [N-Ethyl- and [N,N‘-Diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II): Structure and Cytotoxic/Estrogenic Activity in Breast Cancer Cells;Journal of Medicinal Chemistry;2005-10-14

4. Enantiomerically Pure [1, 2-Diamino-1-(4-fluorophenyl)butane]platinum(II) Complexes: Synthesis and Antitumor Activity against MCF-7 and MDA-MB 231 Breast Cancer and LnCaP/FGC Prostate Cancer Cell Lines;Archiv der Pharmazie;2004-12

5. Cellular and molecular aspects of drugs of the future: oxaliplatin;Cellular and Molecular Life Sciences;2002-11